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Purpose
A cross-sectional survey was conducted to explore the current awareness and use of com-
plementary and alternative medicine (CAM), as well as attitudes toward CAM, in patients
with cancer and their family members in South Korea.
Materials and Methods
Between September 21 and October 31, 2017, a 25-item questionnaire regarding CAM 
experiences among cancer patients and their family members was conducted in 10 oncol-
ogy clinics in South Korea after institutional review board approval at each institution. 
Results
In total, 283/310 patients were analyzed. The median age was 60 years, and 60% were
male. Most of the patients were actively receiving anticancer treatment at the time of the
survey. A total of 106 patients (37%) had experienced a median of two types (interquartile
range, 1 to 3) of CAM. Belief in CAM (odds ratio [OR], 3.015; 95% confidence interval [CI],
1.611 to 5.640) and duration of disease (OR, 1.012; 95% CI, 1.004 to 1.020) were inde-
pendent factors for using CAM in multivariable analysis. Belief in CAM was significantly 
associated with current use of CAM (OR, 3.633; 95% CI, 1.567 to 8.424). Lay referral was
the most common reason for deciding to use CAM, and only 25% of patients (72/283) dis-
cussed CAM with their physicians.
Conclusion
Patient attitudes toward and confidence in CAM modalities were strongly associated with
their CAM experiences, and only a small number of patients had an open discussion about
CAM with their physicians. A patient education program for CAM is needed.
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Introduction
Cancer is a leading cause of death worldwide, including
in South Korea. An estimated 14.1 million new cancer cases
and 8.2 million cancer deaths occurred worldwide in 2012
[1], and a total of 214,701 cancer cases and 76,855 cancer
deaths were reported in South Korea in 2015 [2]. Although
significant medical advancements have led to improvements
in overall survival, cancer remains a source of fear for pati-
ents and family members and is considered by most to be an
incurable and life-threatening disease.
Many cancer patients have expressed interest in comple-
mentary and alternative medicine (CAM). Cancer survivors
have been found to use CAM more than cancer-free popula-
tions [3]. The use of CAM was also found to be increased
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after cancer diagnosis, from 15.6% to 51.8% [4]. Large num-
bers of patients have reported using CAM during anticancer
treatment—48.9% in Italy [5], 37% in Korea [6], and 29% in
the United Kingdom [7]. Cancer patients use CAM in various
situations, from phase I clinical trials [8] to end-of-life care
[6]; CAM use has also been reported in survivors [9].
Cancer patients use CAM for various reasons, including to
alleviate cancer symptoms, enhance immunity, reduce the
side effects of conventional medicine, and even as an alter-
native to conventional medicine [10]. WHO has defined
CAM as “a broad set of health care practices that are not part
of that country’s own tradition or conventional medicine and
are not fully integrated into the dominant health care sys-
tem” [11]. The National Center for Complementary and 
Alternative Medicine (NCCAM) categorized CAM into five
major classes: the whole medical system, mind-body medi-
cine, biologically based practices, manipulative and body-
based practices, and energy medicine [12].
Most CAM modalities have no proven scientific data for
to support their efficacy or safety, and drug interactions with
conventional medicine can occur; thus, CAM could cause 
patients to be exposed to unexpectedly harmful situations
[13]. In addition to the harmful side effects of or drug inter-
actions with CAM, it can negatively impact patient prognosis
by delaying the diagnosis and treatment of cancer [14] and
can have an enormous impact on out-of-pocket costs [15].
This study was conducted to explore the characteristics of
the use of CAM among cancer patients as well as factors rela-
ted to their decision to disclose their use of CAM to their 
oncologists.
Materials and Methods
1. Patients in the survey
This cross-sectional study included both family members
and cancer patients who received treatment between Sep-
tember 21 and October 31, 2017, at 10 oncology clinics in
South Korea.   
2. Data collection
The survey instrument was a 25-item questionnaire, con-
sisting of demographics (2 items: age, sex), oncology-related
variables (6 items: diagnosis, date of diagnosis, stage of can-
cer at the time of diagnosis, current stage of cancer, previous
and current treatment), attitudes toward CAM (3 items: 
belief, self-confidence, unmet need in knowledge), various
aspects of CAM experiences (9 items: types, experiences,
sources, reasons, effectiveness, satisfaction, side effects, 
duration of usage, cost of CAM), and CAM consultation 
experience with a doctor (5 items). CAM types were catego-
rized as follows for practical reasons, and each category has
detailed examples frequently used in South Korea: Chinese
medicine, health supplement, herb/folk remedy/dietary
supplementation, imaginary therapy, and cell therapy, among
others. Four medical oncologists, one radiational oncologist,
and one oncology surgeon developed the questionnaire
based on a literature review. Review, feedback, and revision
of the questionnaire were conducted during investigator
meetings. A paper self-report questionnaire was used for this
survey with the support of clinical research coordinators to
ensure proper data collection. Patients received a gift worth
$5 on the day of survey participation.
3. Statistical analysis
Descriptive statistics, including the means, medians, per-
centages, quartiles, and standard deviations, were used to
summarize the demographics and the survey responses. Stu-
dent’s t test and the Mann-Whitney U test were used to 
determine the differences between the groups. A p-value of
< 0.05 was considered statistically significant. IBM SPSS sta-
tistics ver. 24 (IBM Corp., Armonk, NY) was used for all sta-
tistical analyses. Graphs were produced using Excel software
based on SPSS output data.
4. Ethical statement
The study was approved by the Institutional Review Board
at the Kangdong Sacred Heart Hospital (KANGDONG 2017-
05-006), Soonchunhyang University Hospital Cheonan (SCH-
CA 2017-08-043), Seoul St. Mary's Hospital (KC19QEDI0218),
Seoul National University Bundang Hospital (B-1709/423-
304), Gyeongsang National University Hospital (GNUH
2017-09-008), Keimyung University Dongsan Medical Center
(2017-09-017), Chungnam National University Hospital
(CNUH 2017-09-003), Chonnam National University Hwa-
sun Hospital (CNUHH-2017-135), Catholic Kwandong Uni-
versity International St. Mary's Hospital (IS17QIMI0053), and
Severance Hospital, Yonsei Cancer Center (4-2017-0713).
Written informed consent was obtained from all participants.
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Refused to participate (n=15)
Surveys replied by family members (n=82)
Surveys replied by friends (n=7)
Did not submit the survey (n=1)
Items for incomplete survey 
  No answer to the attitude toward CAM (n=24)
  No answer to the side effects of CAM (n=3)
Patients invited from 
10 oncology clinics (n=415)
Patients submitted
the survey (n=310)
Patients completed
the survey (n=283)
Fig. 1. Study consort diagram. CAM, complementary and alternative medicine.
Table 1.  Demographics according to CAM use 
Characteristic Total  Not experienced Experienced p-value(n=283) (n=177) (n=106)
Age (yr) 60 (52-67) 62 (52-67) 60 (52-67) 0.574a)
Sex
Male 169 (59.7) 113 (63.8) 56 (52.8) 0.068a)
Female 114 (40.3) 64 (36.2) 50 (47.2)
Cancer type
Gastrointestinal tract 109 (38.5) 73 (41.2) 36 (34.0) 0.845b)
Thorax 37 (13.1) 22 (12.4) 15 (14.2)
Hepatobiliary 37 (13.1) 24 (13.6) 13 (12.3)
Breast 36 (12.7) 20 (11.3) 16 (15.1)
GY/GU 26 (9.2) 14 (7.9) 12 (11.3)
Sarcoma 12 (4.2) 7 (4.0) 5 (4.7)
Head and neck 10 (3.5) 7 (4.0) 3 (2.8)
Hematology 8 (2.8) 6 (3.4) 2 (1.9)
Other 8 (2.8) 4 (2.3) 4 (3.8)
Duration of disease (mo) 12 (4-29) 10 (3-22) 20.5 (5-39) < 0.001a)
Advanced disease
Yes 86 (30.4) 59 (33.3) 27 (25.5) 0.379a)
No 125 (44.2) 75 (42.4) 50 (47.2)
Missing 72 (25.4) 43 (24.3) 29 (27.4)
Current treatment
Active treatment 2 (0.7) 2 (1.1) 0 ( 0.792b)
Palliative care 278 (98.2) 173 (97.7) 105 (99.1)
Unknown 3 (1.1) 2 (1.1) 1 (0.9)
Belief in CAM
Yes 204 (72.1) 115 (65.0) 89 (84.0) < 0.001a)
No 79 (27.9) 62 (35.0) 17 (16.0)
Values are presented as median (IQR) or number (%). CAM, complementary and alternative medicine; GY/GU, gynecolog-
ical/genitourinary tumor; IQR, interquartile range. a)Chi-square test, b)Fisher exact test.
Results
1. Participant characteristics
Between September 21 and October 31, 2017, 415 patients
and family members were invited to participate in the sur-
vey. Four hundred patients agreed to take the survey among
the 10 participating oncology clinics in South Korea: the 
response rate was 75% (310/415), and 283 patients completed
the survey (Fig. 1).
In total, 286 of 310 patients reported their attitudes toward
CAM. Among 286 patients, 51 (17.8%) had strong beliefs in
CAM, 156 (54.5%) had weak beliefs in CAM, and 79 (27.6%)
had no beliefs in CAM. The analysis included 283 patients
because three patients did not report the satisfaction of CAM.
The patients’ demographics are summarized in Table 1.
The median age was 61 years, and 60% were male. Most of
the patients were actively receiving anticancer treatment at
the time of the survey. Groups based on the confidence in
CAM modalities were not different in terms of age (p=0.574),
sex (p=0.068), cancer type (p=0.845), or advanced disease at
the time of the survey (p=0.379). However, duration of dis-
ease (p < 0.001) and belief in CAM (p < 0.001) were different
according to the CAM experience.
2. CAM experiences among the patients
A total of 106 patients (37%) had experienced a median of
two CAM modalities (interquartile range [IQR], 1 to 3), and 60
of them continued to use CAM at the time of survey, with a
median of one modality (IQR, 1 to 2). The median duration of
Cancer Res Treat. 2019;51(3):851-860
Fig. 2.  Satisfaction with complementary alternative medicine according to complementary and alternative medicine (CAM)
modalities in 283 patients. (A) Number of patients who are aware of the types of CAM, those who have previously used
CAM, and those who are current CAM users. (B) Satisfaction score (0-10) for each CAM modality in 106 patients. The median
and quartile values are displayed; Q1-Q3, 1st quartile-3rd quartile. NA, not available.
Chinese medicine
High frequency heat therapy
Others
Imaginary therapy
Herb/Folk remedies/
Dietary supplementation
100 150 2000 50
Health supplement
Current experience
27 58 154
40 90 161
22 47 170
7 18 63
1
0 0 2
2 2
Past experience Awareness
A
5 (4-6)
7 (6-7)
6 (5-8)
5 (3-6)
NA
6 8 1040 2
5 (3-6)
Q3-median Q1-median
BSatisfaction score with CAM
Fig. 3.  Patients’ answers on multiple-choice questions regarding their expectations about complementary and alternative
medicine (CAM) before use (left side) and met their expectancy after using CAM (right side).
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Table 2.  Probability of using CAM among patients (n=283)
CAM, complementary and alternative medicine; cOR, crude odds ratio; CI, confidence interval; aOR, adjusted odds ratio
controlling for age, sex, disease duration, and belief in CAM; GI, gastrointestinal tumor; HB, hepatobiliary tumors; GY/GU,
gynecological/genitourinary tumor; HN, head and neck cancer.
Variable cOR (95% CI) aOR (95% CI)
Age (yr) 0.995 (0.973-1.017) 0.996 (0.972-1.020)
Female vs. male 1.576 (0.966-2.572) 1.375 (0.814-2.324)
Diagnosis of cancer
Thorax vs. GI 1.383 (0.641-2.980) -
HB vs. GI 1.098 (0.501-2.406) -
Breast vs. GI 1.622 (0.752-3.500) -
GY/GU vs. GI 1.738 (0.729-4.141) -
Sarcoma vs. GI 1.448 (0.430-4.882) -
HN vs. GI 0.869 (0.212-3.560) -
Hematology vs. GI 0.676 (0.130-3.519) -
Others vs. GI 2.028 (0.479-8.578) -
Disease status
Advanced disease vs. not 1.457 (0.816-2.600) -
Unknown vs. not 1.474 (0.765-2.837) -
Anticancer treatment
Active treatment vs. palliative care > 999.999 (< 0.001-> 999.999) -
Unknown vs. palliative care > 999.999 (< 0.001-> 999.999) -
Disease duration (mo) 1.011 (1.003-1.019) 1.012 (1.004-1.020)
Belief vs. no belief 2.823 (1.543-5.162) 3.015 (1.611-5.640)
Table 3.  Probability of current use of CAM among patients (n=283)
CAM, complementary and alternative medicine; cOR, crude odds ratio; CI, confidence interval; aOR, adjusted odds ratio
controlling for age, sex, disease duration, and belief in CAM; GI, gastrointestinal tumor; HB, hepatobiliary tumors; GY/GU,
gynecological/genitourinary tumor; HN, head and neck cancer.
Variable cOR (95% CI) aOR (95% CI)
Age (yr) 1.007 (0.981-1.034) 1.010 (0.982-1.039)
Female vs. male 1.394 (0.785-2.476) 1.360 (0.742-2.493)
Diagnosis of cancer
Thorax vs. GI 0.811 (0.300-2.194) -
HB vs. GI 1.156 (0.462-2.889) -
Breast vs. GI 1.197 (0.478-3.000) -
GY/GU vs. GI 1.862 (0.714-4.861) -
Sarcoma vs. GI 2.095 (0.576-7.620) -
HN vs. GI 1.048 (0.207-5.299) -
Hematology vs. GI 1.397 (0.263-7.417) -
Others vs. GI 0.599 (0.070-5.132) -
Disease status
Advanced disease vs. not 1.304 (0.647-2.629) -
Unknown vs. not 1.578 (0.730-3.412) -
Anticancer treatment
Active treatment vs. palliative care > 999.999 (< 0.001-> 999.999) -
Unknown vs. palliative care > 999.999 (< 0.001-> 999.999) -
Disease duration (mo) 1.004 (0.996-1.012) 1.004 (0.996-1.012)
Belief vs. no belief 3.609 (1.563-8.331) 3.633 (1.567-8.424)
each CAM modality was 4 months (IQR, 1 to 12). Patients who
continued to use CAM reported belief in the efficacy of CAM
(p < 0.001) and reported that they were actively receiving treat-
ment (p=0.040). A total of 39% of the patients (41/106) 
reported that they started using CAM at the time of diagnosis,
and 27% (29/106) reported that they started during chemo-
therapy. Herb/folk remedy/dietary supplementation was the
most recognized CAM modality, followed by health supple-
mentation, Chinese medicine, and imaginary therapy. The 
patients’ satisfaction score with imaginary therapy was rela-
tively higher than their satisfaction with Chinese medicine,
health supplementation, or herb/folk remedy/dietary supple-
mentation (Fig. 2). Patients’ expectations before using CAM
and the number of answers of patients who felt that the effi-
cacy of CAM met their expectations are presented in Fig. 3.
Enhanced immunity was the most frequently reported 
“expected efficacy” before using CAM, while psychological or
emotional support was the most frequently reported “real 
effect” after using CAM. 
3. Factors related to CAM experiences and continuous use
Among the 283 patients, 106 experienced CAM and 60
used CAM at the time of the survey. Duration of disease and
belief in CAM were significantly related to the experience of
CAM. The odds ratios (ORs) of those two factors were still
significant after controlling for age, sex, disease duration, and
belief in CAM through a multivariable logistic model (dis-
ease duration: OR, 1.012; 95% confidence interval [CI], 1.004
to 1.020; belief in CAM: OR, 3.015; 95% CI, 1.611 to 5.640)
(Table 2). Patients’ belief in CAM was independent of related
factors with current CAM use at the time of the survey after
controlling for age, sex, disease duration, and belief in CAM
through a multivariable logistic model (OR, 3.633; 95% CI,
1.567 to 8.424) (Table 3). Moreover, 26 patients of 106 CAM
users replied that they did not experience any efficacy from
CAM. Eight percent (9/106) reported that they experienced
side effects from CAM, and herbal medication was the most
common cause of side effects. Cancer type, duration of dis-
ease, active treatment, disease duration, and discussion
about CAM with physician were not related to patients’ feel-
Cancer Res Treat. 2019;51(3):851-860
Fig. 4.  Sources of information of complementary and alternative medicine (CAM): tree-map of various sources of information
from all patients for multiple-choice questions on the left side (A) and the percentage of actual sources from multiple-choice
questions and sources that were regarded as reliable by patients from single-choice questions on the right side (B).
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B
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ings of effectiveness, side effects, or satisfaction in age- and
sex-adjusted univariate analysis (S1-S3 Tables). We also
grouped and analyzed the data by belief in CAM. Compared
with those who did not believe in the efficacy of CAM, those
who believed in CAM reported significantly more CAM use,
the current use of a CAM modality and the experience of
CAM efficacy, with ORs of 2.82 (95% CI, 1.54 to 5.16; p <
0.001), 3.61 (95% CI, 1.56 to 8.34; p=0.003), and 3.51 (95% CI,
1.19 to 10.36; p=0.023), respectively. However, neither satis-
faction with CAM nor side  effects were not related to belief
in CAM (S4 Table).
4. Awareness of CAM
Forty-three percent of patients (56/106) started CAM fol-
lowing recommendations from family, relatives, or friends.
Twenty-four percent (25/106) received recommendations
from other patients and their family members. Only 14% of
patients (15/106) started CAM by themselves. Patients gath-
ered their CAM information from various sources, with a 
median number of 3 (range, 1 to 11). The most common
sources of CAM information were family, relatives or friends
(200/634), followed by media (186/634), healthcare profes-
sionals (68/634), social networking sites (62/634), advertise-
ments (45/634), etc. Media (34%), followed by family, rela-
tives, or friends (22%), and health care professionals (20%)
were regarded as reliable sources of information (Fig. 4).
Among the patients, only 7% replied that they had sufficient
knowledge of CAM, and 60% of patients reported that they
had insufficient knowledge of CAM. Patients reported that
they wanted more information about CAM, specifically the
following: scientific evidence for efficacy (28%); clinical trials
with CAM (21%); harmful effects, including side effects (17%);
case reports (11%); guidelines (10%); and an exact definition
(5%).
5. Discussion of CAM with doctors
Only 25% (72/283) discussed CAM with their oncologists.
In most cases (90%), patients or family members started the
discussion about CAM, and only 10% of patients reported that
the discussion about CAM was initiated by healthcare profes-
sionals. These conversations included discussions of efficacy
(42%), side effects (28%), drug interactions with conventional
treatments or other CAM (26%), the appropriate use of CAM
(2%), and restrictions during chemotherapy (1%). Common
reasons for not asking physicians in 211 patients were “not a
matter to discuss with a doctor” (49%, 103/211), “physicians
hate to discuss CAM” (23%, 48/211), and “physicians will stop
my use of CAM (18%, 38/211), among others.
Discussion
In our study population, positive attitudes regarding the
safety and efficacy of CAM and duration of disease were 
associated with the experience of CAM. This result is similar
to the results of a previous study that investigated the atti-
tudes and beliefs related to CAM in cancer patients in the
United States [16]. In this study by Bauml et al. [16], attitudes
and beliefs related to CAM had a greater impact on the use
of CAM than demographic variables such as age or sex. In
this study, barriers to CAM had a negative association with
the use of CAM. In contrast with the results of other studies,
age and sex were not related to either the use of CAM or 
attitudes toward CAM in our study. The relatively lower rate
of the use of CAM (37.5% vs. 58.5%), the heterogeneous dis-
ease group in our study population and possible cultural dif-
ferences might explain these differences. The use of CAM has
also been reported to have a positive association with holistic
needs or concerns related to the toxicity of conventional med-
icine. In our study, we did not ask questions related to these
concerns or barriers related to the use of CAM [17]. Addi-
tional studies are needed to further explore patient attitudes
and beliefs regarding CAM use.
The prevalence of CAM use has increased in Western
countries, and out-of-pocket costs for CAM modalities is
enormous [18,19]. Legislation systems in European countries
and the United States should make the market more trans-
parent, which may enable greater CAM use. However, 
because scientific studies on the safety and effectiveness of
CAM modalities are lacking, more flexible standards are 
applied to them than to conventional medicine [20]. Varia-
tions in regulations among European countries are consid-
ered “a substantial lack of understanding of the risks among
healthcare policymakers”. CAM legislation must be aligned
with the regulations of conventional healthcare systems to
ensure patient safety. The regulation of CAM modalities in
Canada and the United States has minimal requirements for
registration [21]. Some may argue that CAM has already
been incorporated into conventional medication under the
name of integrative medicine, and many cancer centers in the
United States already provide integrative oncology in their
cancer care strategies. Regardless of whether integrative 
oncology is promoted in cancer care, more translational
and/or clinical research is needed to understand the under-
lying mechanisms and clinical efficacy in terms of quality of
life and overall survival, as well as to reduce the side effects
of conventional medicine, the impact on adherence to con-
ventional medicine, and drug interactions between integra-
tive medicine and conventional oncology drugs. Until now,
Asian countries have not reported enough data to provide
sufficient knowledge of CAM to professionals and lay per-
Cancer Res Treat. 2019;51(3):851-860
sons compared to the United States or European countries.
The possibility of exposing cancer patients to unexpected
harm due to CAM use in Korea is what motivated us to take
the first step to fill this knowledge gap by conducting this
survey.
In addition to the paucity of scientific studies on CAM, 
patients’ attitudes about disclosing their use of CAM to their
primary care physicians are concerning. In our study, only
25% (72/283) discussed using CAM with their physicians,
and most of these discussions were initiated by patients or
family members, not by physicians. Other studies have 
reported that less than 50% of patients disclose their use of
CAM to their healthcare providers, and they do not disclose
all types of CAM modalities [22]. Disclosure was associated
with patient-related factors, including sex, ethnicity or edu-
cation level, as well as their healthcare provider’s perspective
on CAM [23]. Non-Hispanic ethnicity, female sex, and a rel-
atively high level of education were related to their disclo-
sure of their use of CAM [24]. Patients tended to disclose
their CAM use when the provider placed more value on
CAM modalities [23]. Even though patients should be able
to receive information on CAM from the healthcare profes-
sionals at the time when they consider using CAM, they do
not disclose their desire to use CAM for the following rea-
sons: (1) fear of being abandoned by their cancer doctors 
because they wish to use CAM modalities, (2) physician’s
lack of knowledge of CAM, or (3) fear of upsetting their
physician [25]. The reasons for not having a discussion about
CAM in our study were as follows: physicians hate to discuss
CAM, physicians will stop my use of CAM, physicians have
no knowledge of CAM, and it is not a matter for discussion
with physicians. These reasons for not having a discussion
with their physicians are similar to those reported in other
studies. Patients do not disclose their use of CAM not only
because of their physician’s lack of knowledge of CAM but
also because they do not want to discuss their dissatisfaction
with the conventional medical system [26]. To facilitate the
discussion of CAM between patients and physicians, CAM
education programs should be developed—not only for 
patients but also for physicians [27]. Developing an educa-
tion program for CAM could help improve patient-doctor
communication related to CAM and protect patients from
unexpected, harmful effects of CAM.
Patients’ sources of information constitute another prob-
lem that remains to be solved. Physicians as well as patients
need more information about CAM. In our study, 132 pati-
ents wanted information related to the scientific evidence of
CAM efficacy, and 96 wanted to know about clinical trials
on CAM. However, their sources of information were family,
relatives, and friends (32%) and media and social networking
sites (40%), with their most trusted source of information
being media (34%). Another study reported that lay referral
and media were also used by cancer patients to gather infor-
mation about CAM [28]. Family endorsement was also 
reported to affect patients’ expectations of CAM in terms of
clinical efficacy [29]. It is not easy to find scientific evidence
on CAM in Korean on websites; therefore, we need to focus
on ensuring that these data are available to Korean patients.
The design of this cross-sectional study has some limita-
tions in confirming the relationships between patients’ 
expectations of CAM efficacy and their feelings of effective-
ness and satisfaction. Young age, chronic illness, including
cancer, and level of education were reported to have impacts
on the use of CAM or CAM experiences. Cancer type has also
been associated with CAM-related behaviors. To validate our
study, prospective observational studies are needed that con-
trol for confounding factors.
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